503162 — Reliance Chemotex Industries Balance Sheet
0.000.00%
- IN₹1.18bn
- IN₹3.62bn
- IN₹3.59bn
- 27
- 44
- 41
- 26
Annual balance sheet for Reliance Chemotex Industries, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 328 | 576 | 613 | 504 | 112 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 251 | 262 | 354 | 479 | 595 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 1,061 | 1,309 | 1,461 | 1,563 | 1,531 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1,474 | 1,890 | 2,324 | 3,158 | 3,103 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 2,626 | 3,332 | 3,970 | 4,810 | 4,744 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1,025 | 1,367 | 1,654 | 1,639 | 1,680 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 1,583 | 2,118 | 2,650 | 3,474 | 3,371 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 1,044 | 1,214 | 1,320 | 1,336 | 1,373 |
| Total Liabilities & Shareholders' Equity | 2,626 | 3,332 | 3,970 | 4,810 | 4,744 |
| Total Common Shares Outstanding |